| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| FOR-46 | FOR-46; FG-3246 | Phase 2 Clinical | University Of California San Diego, Fortis Therapeutics Inc | Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma; Prostatic Neoplasms | Details |
| Enadenotucirev | ColoAd-1; Oncolytic Ad11/Ad3 | Phase 1 Clinical | Akamis Bio Ltd | Ovarian Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colonic Neoplasms; Neoplasms, Glandular and Epithelial; Urinary Bladder Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| YS-5 | YS-5 | Phase 1 Clinical | Fortis Therapeutics Inc, United States Department Of Defense | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |




